Latest Conference Articles

June 11th 2022, 6:55pm

European Hematology Association Congress

Jeff Sharman, MD, discusses 5-year follow-up data from the phase 3 Elevate CLL TN trial in treatment-naïve patients with chronic lymphocytic leukemia.

June 11th 2022, 6:30pm

European Hematology Association Congress

Musa Yilmaz, MD, discusses composite complete remission and bone marrow transplant rates observed in a phase 1/2 trial in patients with FLT3-ITD–mutated acute myeloid leukemia.

June 11th 2022, 4:41pm

European Hematology Association Congress

Momelotinib demonstrated significant improvements in symptoms, spleen size, and anemia measures compared with danazol in patients with symptomatic and anemic myelofibrosis who previously received treatment with a JAK inhibitor.

June 11th 2022, 3:45pm

European Hematology Association Congress

Decitabine demonstrated a comparable overall survival and rate of hematopoietic stem cell transplant in addition to a lower incidence of adverse effects vs induction chemotherapy with daunorubicin and cytarabine in older patients at least 60 years of age with acute myeloid leukemia.

June 11th 2022, 1:10pm

European Hematology Association Congress

ARI0002H, a BCMA-directed CAR T-cell therapy, achieved promising response rates in patients with relapsed/refractory multiple myeloma, according to findings from a phase 1/2 trial.

June 11th 2022, 11:04am

European Hematology Association Congress

Time-limited targeted therapy with venetoclax plus obinutuzumab with or without ibrutinib demonstrated superior progression-free survival outcomes compared with standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.

June 11th 2022, 10:44am

European Hematology Association Congress

The addition of quizartinib to standard induction and consolidation chemotherapy and then continued as a single agent doubled median overall survival vs standard chemotherapy alone in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

June 10th 2022, 8:36pm

European Hematology Association Congress

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

June 10th 2022, 8:27pm

European Hematology Association Congress

Raul Cordoba, MD, PhD, discusses efficacy data with epcoritamab observed in the phase 1/2 EPCORE NHL-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

June 10th 2022, 8:08pm

European Hematology Association Congress

Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic leukemia assigned to zanubrutinib reported better health-related quality of life than those administered ibrutinib.

June 10th 2022, 8:06pm

Single-agent acalabrutinib continued to showcase favorable efficacy, with a notable benefit in progression-free survival benefit over standard-of-care regimens and a consistent toxicity profile, in patients with relapsed/refractory chronic lymphocytic leukemia.

June 10th 2022, 7:45pm

European Hematology Association Congress

Epcoritamab in combination with gemcitabine plus oxaliplatin displayed encouraging responses with no new safety signals among patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant, according to initial results from the phase 1b/2 EPCORE NHL-2 trial.

June 10th 2022, 7:25pm

European Hematology Association Congress

Epcoritamab plus rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin displayed encouraging responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are eligible for autologous stem cell transplant, according to preliminary results from arm 4 of the phase 1b/2 EPCORE NHL-2 trial.

June 10th 2022, 6:01pm

European Hematology Association Congress

Single-agent pirtobrutinib is being investigated for safety and efficacy in heavily pretreated, BTK inhibitor–naïve patients with mantle cell lymphoma in the ongoing phase 3 BRUIN-MCL-321 trial.

June 10th 2022, 5:07pm

European Hematology Association Congress

Oral azacitidine was associated with improved long-term survival in patients with acute myeloid leukemia who harbored NPM1 mutations, had intermediate-risk cytogenetics at diagnosis, had a longer treatment duration, or a minimal residual disease response during treatment.

June 10th 2022, 5:00pm

European Hematology Association Congress

The combination of the PD-1 antibody sintilimab and decitabine elicited potent clinical activity and manageable safety with no grade 4 or 5 treatment-related adverse effects as frontline therapy in patients with higher-risk myelodysplastic syndrome, according to preliminary results from a phase 2 trial.

June 10th 2022, 4:44pm

European Hematology Association Congress

The fixed-duration, frontline combination comprised of ibrutinib and venetoclax continued to produce deep, durable responses with a clinically meaningful progression-free survival benefit in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

June 9th 2022, 9:00pm

ASCO Annual Meeting

Adding toripalimab to chemotherapy in the frontline setting demonstrated improved progression-free survival vs placebo plus chemotherapy in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.

June 9th 2022, 6:52pm

ASCO Annual Meeting

Zanubrutinib continued to demonstrate a higher complete response or very good partial response rate and less off-target activity compared with ibrutinib in patients with MYD88-mutated Waldenström macroglobulinemia.

June 9th 2022, 3:35pm

ASCO Annual Meeting

Tislelizumab plus chemotherapy continued to improve progression-free survival over chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated data from the RATIONALE-309 trial.